Verastem | VSTM - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
AstraZeneca USD 12.39B 5M 2025-12
Curis USD 1.14M 8.86M 2025-12
Cytokinetics USD 17.76M 15.82M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Incyte USD 1.39B 118.68M 2025-12
Laboratory Of America USD 993.2M 31.9M 2025-12
Novartis USD 10.25B 570M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Roche Holding CHF 22.09B 10.04B 2025-12
TG Therapeutics USD 154.43M 20.81M 2025-12
Verastem USD 14.64M 14.1M 2025-12